GB2602019A — Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof

USPTO Abstract

A compound of Formula I or a salt thereof: The compound of Formula I is for use as a medicament, for use in the treatment of epilepsy. A pharmaceutical composition comprising a compound of Formula I is also disclosed. The pharmaceutical composition may be a tablet, capsule, granule, powder for inhalation, sprinkle, oral solution or a suspension. The pharmaceutical composition may additionally comprise an excipient, disintegrant, lubricant, stabilizer, flavouring agent, antioxidant, diluent or another pharmaceutically effective compound. The compound of the invention is a cannabinoid derivative, an analogue of cannabidiol (CBD). The compound of the invention is (1’R,2’R)-5’-methyl-4-(1-methyl-1H-pyrazol-4-yl)-2’-(prop-1-en-2-yl)-1’,2’,3’,4’-tetrahydro-[1,1’-biphenyl]-2,6-diol. Also claimed is a process for the production of a compound of Formula I comprising coupling menthadienol with phloroglucinol, reacting the intermediate via triflation reaction to produce an aryl triflate intermediate, followed by subsequent steps to produce the compound of Formula I.